At the time of the event, there was no indication of a reportable malfunction based on information provided and assessed by alere (b)(4).Alere (b)(4) updated reporting decisions and conducted a retrospective review of complaints against the updated reporting decisions.This mdr is a retrospective filing that was identified during this retrospective review activity associated with an observation from an fda inspection conducted in january 2019 at alere (b)(4) (reference eir (b)(4)).The awareness date is based on updated reporting decisions and completion of the retrospective review activity.There is no new or increased trend based on this retrospective review activity.Investigation results: customer's observation was not replicated in-house with retention devices.Retention devices were tested with 25 miu/ml cutoff hcg urine control and 3 high level of hcg urine controls (205.2 iu/ml, 208.6 iu/ml and 216.8 iu/ml), all results were positive at read time and met qc specification.Mfg batch record review did not uncover any abnormalities.Root cause could not be determined without patient specimen in-house analysis and insufficiency information provided.
|
It was reported that the hcg test had a readability issues with faint test lines which could be missed by staff.There was no report of patient harm.Troubleshooting with the customer did not indicate any technique, sample interference, or other factors contributing to the positive result.
|